Orphan status for ChemGenex
Tuesday, 20 January, 2009
Melbourne’s ChemGenex has been granted orphan drug status for its apoptopic drug omacetaxine mepesuccinate from the US FDA.
The orphan drug status is for use in myelodysplastic syndromes, a range of bone marrow stem cell disorders. May sufferers die from infection while some develop acute myelogenous leukaemia.
The drug is also currently in Phase II trials for chronic myeloid leukaemia. The drug induces apoptosis by inhibiting protein synthesis and is being trialled in people with a mutation in the T3151 gene, who are often resistant to the front-line drug imatinib (Glivec).
3D-printed films provide targeted liver cancer treatment
Researchers have created drug-loaded, 3D-printed films that kill more than 80% of liver cancer...
Using your brain at work may ward off cognitive impairment
The harder your brain works at your job, the less likely you may be to have memory and thinking...
Repurposed drugs show promise in heart muscle regeneration
The FDA-approved medications, when given in combination, target two proteins that regulate the...